Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Sep;11(9):e002228.
doi: 10.1161/CIRCGEN.118.002228.

Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings

Affiliations
Randomized Controlled Trial

Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings

Bruce Peyser et al. Circ Genom Precis Med. .

Abstract

Background: Outcomes of tailoring statin-type based on solute carrier organic anion transporterfamily member 1B1 ( SLCO1B1)pharmacogenetic toxicity information on patient, provider, and pharmacological outcomes are unknown.

Methods: The trial randomized 159 patients not taking statins because of prior statin myalgia 1:1 to receiving SLCO1B1 GIST (Genotype Informed Statin Therapy) versus usual care (UC) and followed for up to 8 months. The UC arm received their SLCO1B1 results post-trial. The primary outcome was statin adherence using the Morisky Medication Adherence Scale, which was assessed in those patients who reinitiated statins. Secondary outcomes assessed in all participants included statin reinitiation and LDLc (low-density lipoprotein cholesterol), within and post-trial. Using commercial laboratory data, serial LDLc were compared between 1907 patients receiving SLCO1B1 testing and propensity-matched, untested controls.

Results: Trial participants were 25% SLCO1B1*5 carriers. Statin adherence was similar between arms (Morisky Medication Adherence Scale in GIST versus UC, 6.8±1.5 versus 6.9±1.6, P=0.96). GIST led to more new statin prescriptions (55.4% versus 38.0%, P=0.04) and lower LDLc at 3 months (131.9±42.0 versus 144.4±43.0 mg/dL; P=0.048) with similar magnitude at 8 months (128.6±37.9 versus 141.0±44.4; P=0.12). SLCO1B1*5 carriers exhibited a greater drop in LDLc with GIST versus UC (interaction P=0.048). Post-trial, LDLc decreased in UC participants who crossed over to GIST compared with those allocated to GIST (-14.9±37.8 versus +9.0±37.3 mg/dL, P=0.03). Patients tested for SLCO1B1 though a commercial laboratory had a greater LDLc decrease ( P=0.04) compared with controls.

Conclusions: Delivery of SLCO1B1 pharmacogenetic testing that addresses statin myalgia improved statin reinitiation and LDLc but did not improve self-reported statin adherence.

Clinical trial registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01894230.

Keywords: SLCO1B1 protein; clinical trial; genotype; hydroxymethylglutaryl-CoA reductase inhibitors; myalgia; patients; pharmacogenetics.

Comment in

  • SLCO1B1 and Statin Therapy.
    Tuteja S, Rader DJ. Tuteja S, et al. Circ Genom Precis Med. 2018 Sep;11(9):e002320. doi: 10.1161/CIRCGEN.118.002320. Circ Genom Precis Med. 2018. PMID: 30354338 No abstract available.

Similar articles

See all similar articles

Cited by 4 articles

Publication types

MeSH terms

Substances

Associated data

Feedback